- Home
- CLGN vs PLUR Comparison
CLGN vs PLUR Comparison
Compare CLGN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- PLUR
- Stock Information
- Founded
- CLGN 2004
- PLUR 2001
- Country
- CLGN Israel
- PLUR Israel
- Employees
- CLGN N/A
- PLUR N/A
- Industry
- CLGN Industrial Specialties
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLGN Health Care
- PLUR Health Care
- Exchange
- CLGN Nasdaq
- PLUR Nasdaq
- Market Cap
- CLGN 33.8M
- PLUR 36.9M
- IPO Year
- CLGN N/A
- PLUR N/A
- Fundamental
- Price
- CLGN $2.11
- PLUR $3.80
- Analyst Decision
- CLGN Strong Buy
- PLUR Strong Buy
- Analyst Count
- CLGN 2
- PLUR 1
- Target Price
- CLGN $11.50
- PLUR $12.00
- AVG Volume (30 Days)
- CLGN 20.8K
- PLUR 53.4K
- Earning Date
- CLGN 11-26-2025
- PLUR 11-12-2025
- Dividend Yield
- CLGN N/A
- PLUR N/A
- EPS Growth
- CLGN N/A
- PLUR N/A
- EPS
- CLGN N/A
- PLUR N/A
- Revenue
- CLGN $2,475,000.00
- PLUR $1,326,000.00
- Revenue This Year
- CLGN $1,617.28
- PLUR $97.38
- Revenue Next Year
- CLGN $83.54
- PLUR $293.97
- P/E Ratio
- CLGN N/A
- PLUR N/A
- Revenue Growth
- CLGN 280.77
- PLUR 121.74
- 52 Week Low
- CLGN $1.31
- PLUR $3.22
- 52 Week High
- CLGN $4.98
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- CLGN 52.69
- PLUR 48.43
- Support Level
- CLGN $1.96
- PLUR $3.60
- Resistance Level
- CLGN $2.24
- PLUR $4.12
- Average True Range (ATR)
- CLGN 0.15
- PLUR 0.38
- MACD
- CLGN 0.03
- PLUR 0.02
- Stochastic Oscillator
- CLGN 95.00
- PLUR 34.27
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.